Genetic risk for co-occurrence of type 1 diabetes and celiac disease is modified by HLA-C and killer immunoglobulin-like receptors

Tissue Antigens

Volumn 84, Issue 5, 2014, Pages 471-478

  Smigoc Schweiger, D ^a   Mendez, A ^b   Kunilo Jamnik, S ^b   Bratanic, N ^a   Bratina, N ^a   Battelino, T ^a,c   Brecelj, J ^a   Vidan Jeras, Blanka ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Celiac disease; Co occurrence; Human leukocyte antigen class I; Killer cell immunoglobulin like receptor; Receptor ligand interaction; Type 1 diabetes

Indexed keywords

HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DP1; UNCLASSIFIED DRUG; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KIR2DL2 PROTEIN, HUMAN; KIR2DL3 PROTEIN, HUMAN;

ARTICLE; CELIAC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HLA TYPING; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOGENE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; PREVALENCE;

CELIAC DISEASE; COMORBIDITY; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-C ANTIGENS; HUMANS; MALE; PREVALENCE; RECEPTORS, KIR2DL2; RECEPTORS, KIR2DL3;

EID: 84933520549     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12450     Document Type: Article

References (47)

1. Radosevic B, Bukara-Radujkovic G, Miljkovic V, Pejicic S, Bratina N, Battelino T. The incidence of type 1 diabetes in Republic of Srpska (Bosnia and Herzegovina) and Slovenia in the period 1998-2010. Pediatr Diabetes 2013: 14: 273-9.
2. Dovc K, Telic SS, Lusa L et al. Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. Diabetes Technol Ther 2014: 16: 33-40.
3. Sud S, Marcon M, Assor E, Palmert MR, Daneman D, Mahmud FH. Celiac disease and pediatric type 1 diabetes: diagnostic and treatment dilemmas. Int J Pediatr Endocrinol 2010: 2010: 161285.
4. Diamanti A, Capriati T, Bizzarri C et al. Celiac disease and endocrine autoimmune disorders in children: an update. Expert Rev Clin Immunol 2013: 9: 1289-301.
5. Cerutti F, Bruno G, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004: 27: 1294-8.
6. Larsson K, Carlsson A, Cederwall E et al. Annual screening detects celiac disease in children with type 1 diabetes. Pediatr Diabetes 2008: 9: 354-9.
7. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol 2013: 9: 646-59.
8. Larizza D, Calcaterra V, Klersy C et al. Common immunogenetic profile in children with multiple autoimmune diseases: the signature of HLA-DQ pleiotropic genes. Autoimmunity 2012: 45: 470-5.
9. Jahromi MM, Eisenbarth GS. Genetic determinants of type 1 diabetes across populations. Ann N Y Acad Sci 2006: 1079: 289-99.
10. Karell K, Louka AS, Moodie SJ et al. European Genetics Cluster on Celiac Disease. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003: 64: 469-77.
11. Battelino T, Ursic-Bratina N, Dolzan V et al. The HLA-DRB, -DQB polymorphism and anti-insulin antibody response in Slovenian patients with type 1 diabetes. Eur J Immunogenet 2003: 30: 223-7.
12. Dolinsek J, Micetik-Turk D, Urlep-Zuzej D, Zagradisnik B, Haimilia K, Holopainen P. Importance of celiac disease patients lacking HLA DQ2 or DQ8 heterodimer in Slovenia. J Pediatr Gastroenterol Nutr 2006: 42: E18-9.
13. Lambert AP, Gillespie KM, Thomson G et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 2004: 89: 4037-43.
14. Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 2003: 61: 105-17.
15. Howson JM, Walker NM, Clayton D, Todd JA. Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009: 11: 31-45.
16. Price P, Witt C, Allcock R et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999: 167: 257-74.
17. Horton R, Gibson R, Coggill P, Miretti M et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics 2008: 60: 1-18.
18. Aly TA, Eller E, Ide A et al. Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype. Diabetes 2006: 55: 1265-9.
19. Bilbao JR, Calvo B, Aransay AM et al. Conserved extended haplotypes discriminate HLA-DR3-homozygous Basque patients with type 1 diabetes mellitus and celiac disease. Genes Immun 2006: 7: 550-4.
20. Smyth DJ, Plagnol V, Walker NM et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008: 359: 2767-77.
21. Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes 2010: 17: 126-30.
22. Maiuri L, Ciacci C, Ricciardelli I et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003: 362: 30-7.
23. Cooper MA, Colonna M, Yokoyama WM. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009: 10: 1103-10.
24. Schleinitz N, Vely F, Harle J-R, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010: 131: 451-8.
25. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010: 10: 501-13.
26. Grose RH, Thompson FM, Cummins AG. Deficiency of 6B11+invariant NK T cells in celiac disease. Dig Dis Sci 2008: 53: 1846-51.
27. Bryceson YT, Chiang SCC, Darmanin S et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011: 3: 216-26.
28. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004: 16: 626-33.
29. IPD - KIR Database. http://www.ebi.ac.uk/ipd/kir/introduction.html.
30. Takeshita LY, Gonzalez-Galarza FF, dos Santos EJ et al. A database for curating the associations between killer cell immunoglobulin-like receptors and diseases in worldwide populations. Database 2013: 2013: bat021.
31. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011: 132: 315-25.
32. Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012: 24: 239-45.
33. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol 2012: 3: 336.
34. Falco M, Moretta L, Moretta A, Bottino C. KIR and KIR ligand polymorphism: a new area for clinical applications? Tissue Antigens 2013: 82: 363-73.
35. Kuśnierczyk P. Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front Immunol 2013: 4: 8.
36. van der Slik AR, Alizadeh BZ, Koeleman BP, Roep BO, Giphart MJ. Modelling KIR-HLA genotype disparities in type 1 diabetes. Tissue Antigens 2007: 1: 101-5.
37. Meresse B, Curran SA, Ciszewski C et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006: 203: 1343-55.
38. Fernandez-Jimenez N, Santín I, Irastorza I et al. Upregulation of KIR3DL1 gene expression in intestinal mucosa in active celiac disease. Hum Immunol 2011: 72: 617-20.
39. Bratanic N, Smigoc Schweiger D, Mendez A, Bratina N, Battelino T, Vidan-Jeras B. An influence of HLA-A, B, DR, DQ and MICA on the occurrence of celiac disease in patients with type 1 diabetes. Tissue Antigens 2010: 76: 208-15.
40. Husby S, Koletzko S, Korponay-Szabó IR et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012: 54: 136-60.
41. de Smith AJ, Walsh KM, Ladner MB et al. The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia. Blood 2014: 17: 2497-503.
42. VandenBussche CJ, Mulrooney TJ, Frazier WR, Dakshanamurthy S, Hurley CK. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun 2009: 10: 162-73.
43. Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and coeliac disease. Lancet 1997: 349: 1096-7.
44. Mazzarella G, Stefanile R, Camarca A. Gliadin activates HLA class 1- restricted CD8+ T cells in celiac disease intestinal mucosa and induces the enterocyte apoptosis. Gastroenterology 2008: 134: 1017-27.
45. Fasano ME, Rendine S, Pasi A et al. The distribution of KIR-HLA functional blocks is different from north to south of Italy. Tissue Antigens 2014: 83: 168-73.
46. Allele frequency net. http://www.allelefrequencies.net/kir6002a.asp
47. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008: 180: 3969-79.